University of Chicago and IDefine Launch Innovative Programmable RNA Therapy Program for Kleefstra Syndrome

The University of Chicago and IDefine are developing programmable RNA activators to restore protein levels in Kleefstra syndrome patients, targeting genetic roots.

By: AXL Media

Published: Mar 27, 2026, 7:25 AM EDT

Source: Information for this report was sourced from University of Chicago

Targeting Haploinsufficiency Through Advanced Molecular Engineering

Kleefstra syndrome is a rare neurodevelopmental disorder caused by a specific genetic state known as haploinsufficiency, where a single functional copy of the EHMT1 gene fails to produce enough protein for normal brain function. This deficiency leads to a spectrum of challenges, including intellectual disabilities, autism features, and significant developmental delays. The new research program at the University of Chicago seeks to bypass traditional gene replacement by using molecular tools to "dial up" the production of proteins from the existing, healthy copy of the gene. According to the research team, this approach treats the root cause of the disorder rather than just managing its symptoms.

Leveraging Proven RNA Activation Platforms for Rare Diseases

The Dickinson Lab specializes in synthetic biology and has previously demonstrated success in targeting other genetic conditions, such as Dravet syndrome, using similar programmable translational activation technologies. By applying these established platforms to the EHMT1 gene, researchers aim to create custom "activators" that can precisely increase protein synthesis. This methodology is highly programmable, meaning the core technology can be adapted to recognize and boost specific genetic transcripts. This flexibility makes Kleefstra syndrome an ideal candidate for translational upregulation therapy, as the biological machinery for protein production is already present but underperforming.

Strategic Collaboration Between Academic Research and Patient Advocacy

This initiative is powered by a strategic partnership with IDefine, a nonprofit foundation dedicated to finding cures for Kleefstra syndrome by connecting families with the scientific community. The collaboration ensures that the research remains focused on clinical relevance and the urgent needs of the patient community. Supported by an initial grant from IDefine, the six month project serves as a critical bridge between laboratory innovation and potential human application. By combining the University of Chicago's technical expertise in chemistry with IDefine’s mission-driven resources, the partnership accelerates the path toward a viable therapeutic intervention.